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Case report
An otherwise healthy 61-year-old female presented with a skin tumor on the left flank, which had been present since her 
early adulthood. The tumor gradually enlarged during the first 2–3 years and then stabilized in size. There were no symp-
toms from the tumor. On examination, a red to violaceous, shiny, polypoid, fusiform nodule with firm consis tency, measur-
ing approximately 3.0 cm × 2.0 cm, was noted on her left flank (Figure 1). There were also many skin tumors on her face and 
scalp, most of which were dome-shaped, smooth surfaced, violaceous, firm nodules measuring several millimeters in 
diameter. These tumors were 1-cm dermal nodules that caused pain; others were rounded, skin-colored, firm papules with 
a size of approximately 5 mm in diameter around her nose. An excisional biopsy specimen was obtained from the tumor at 
the flank.
Histopathologic examination revealed a tumor occupying the reticular dermis, which was composed of aggregations of 
neoplastic cells arranged in a jigsaw puzzle pattern. The aggregations consisted of neoplastic cells with two different ap-
pearances: (1) peripheral cells aligned in a palisade with small, dark staining columnar nuclei surrounded by a scant cyto-
plasm, and (2) cells with nuclei that were larger and paler, and that had a more abundant pale cytoplasm. Each aggregation 
was surrounded by a rim of homogenous eosinophilic basement membrane-like material. Globules of the same material 
were also present within the aggregations themselves (Figure 2).
The patient then underwent several sessions of surgical removal for other tumors on the face and scalp, and pathology 
exams showed cylindroma, spiradenoma, trichoepithelioma, or combinations of them (Figure 3A: cylindroma + trichoepi-
thelioma; Figure 3B: cylindroma + spiradenoma). She reported that two of her younger brothers and sisters also had similar 
skin tumors, but they were not as numerous as hers.
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Figure 1 A fusiform nodule on the patient’s left flank. Figure 2 Peripheral columnar cells and central cells with abundant 
cytoplasms (H&E, 400×).
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Diagnosis
Cylindroma and Brooke-Spiegler syndrome.
Discussion
Cylindroma is a common benign adnexal tumor, which is 
most often seen on the head, neck and scalp. It usually pres-
ents as a dome-shaped, shiny nodule. Scalp lesions may 
grow to a large size and coalescence of numerous lesions is 
known as a “turban tumor.” Development on the trunk or 
polypoid appearance is exceptional. There is a marked 
female preponderance of cylindroma (up to 9:1). Familial 
cases have been described and are typically associated 
with multiple tumors. Multiple cylindromas may be associated 
with trichoepitheliomas and spiradenomas, a constellation 
known as Brooke-Spiegler syndrome, which is inherited in an 
autosomal dominant fashion.1 Patients with this syndrome 
occasionally develop multiple basal cell adenomas, milia, 
organoid nevi, and basal cell carcinoma. There is a high 
penetrance in affected families, but the individual clinical 
manifestation is highly variable.
Brooke-Spiegler syndrome is caused by germline muta-
tions in a single gene, called CYLD, located on chromosome 
16q12–q13. Most of the mutations, which are mainly loca-
ted at the C-terminal half of the CYLD coding sequence, 
lead to the formation of truncated proteins.2 The function 
of CYLD is not fully understood. It belongs to a family of 
ubiquitin-specific proteases, and interacts with NEMO, the 
regulatory subunit of the inhibitor κB kinase complex, tumor 
necrosis factor receptor-associated factors (TRAFs), and TRAF-
interacting proteins; it negatively regulates the nuclear factor 
κB signal transduction pathway. Inhibition of CYLD enhances 
activation of the nuclear factor κB and leads to increased 
resistance to apoptosis and advanced carcinogenesis.3
Mutation screening of the CYLD gene should be consid-
ered for patients with multiple cylindromas and/or trichoepi-
theliomas, as well as for their relatives. Early identification 
of Brooke-Spiegler syndrome may improve therapeutic man-
agement to avoid complications such as disfigurement and 
malignant transformation.3
Treatment modalities of these tumors reported in the 
literature are mainly ablative, including surgical removal, 
cryotherapy, electrodessication, topical trichloroacetic acid 
application, and CO2 and Er:YAG laser.4 It has been re-
ported that the effect of CYLD mutation can be reversed 
by application of salicylates or prostaglandin A.5 This find-
ing may provide directions for future novel therapy for this 
syndrome.
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Figure 3 (A) Cylindroma (left) and trichoepithelioma (right) (H&E, 40×). (B) Cylindroma (right) and spiradenoma (left) (H&E, 100×).
